Evidence map›Paper›PMID 36426138›Full record

ArticleJournal of immunology research2022

Cytomegalovirus-Specific T Cells from Third-Party Donors Successfully Treated Refractory Cytomegalovirus Retinitis after Unrelated Umbilical Cord Blood Transplantation.

Na Li, Guangyu Sun, Lihua Zhu, Kang Ding, Huilan Liu, Xiaoyu Zhu, Baolin Tang, Wen Yao, Xiang Wan, Liangquan Geng and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Na LiWannan Medical College, Graduate School, Anhui Wuhu 241002, China.
Guangyu SunDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Lihua ZhuWannan Medical College, Graduate School, Anhui Wuhu 241002, China.
Kang DingWannan Medical College, Graduate School, Anhui Wuhu 241002, China.
Huilan LiuDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Xiaoyu ZhuDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Baolin TangDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Wen YaoDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Xiang WanDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Liangquan GengDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Ping QiangDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Kaidi SongDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Changcheng ZhengDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Zimin SunDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Juan TongDepartment of Hematology of Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.ORCID https://orcid.org/0000-0002-1567-3625

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Umbilical cord blood (UCB) transplants (UCBTs) are becoming increasingly common in the treatment of a variety of hematologic and nonhematologic conditions. The T cells from UCB are naïve T cells, which have not yet been exposed to antigens and therefore do not contain T cells with specific immune functions against viruses. Cytomegalovirus (CMV) infections occur in more than 80% of patients after UCBT compared to other types of transplantation. Anti-CMV medications are currently restricted, with ganciclovir, foscarnet, and valganciclovir being the most common in China; however, with limited efficacy and considerable side effects, all these drugs are susceptible to viral resistance. In recent years, cytomegalovirus-specific T cells (CMVST) have advanced the treatment of viral infections in immunodeficient patients. CMVST usually uses the same donor as hematopoietic stem cell transplantation. CMVST should be administered to UCBT patients because of the absence of donors after UCBT. In China, there is no report on the use of CMVST to treat CMV infection after UCBT, and foreign reports are also limited. This paper reported a 20-year-old male patient with acute myeloid leukemia who developed cytomegalovirus retinitis (CMVR) after umbilical cord blood transplantation. After ineffective viral treatment, he was treated with a third-party donor CMVST and was successfully transformed into CMV nucleic acid negative.

Indexed as

Cord Blood Stem Cell TransplantationCytomegalovirus RetinitisHematopoietic Stem Cell TransplantationAdultCytomegalovirusHumansMaleT-LymphocytesYoung Adult

Identifiers

PMID36426138
PMCPMC9681565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.